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Summary
Background and objectives The discovery of different podocyte autoantibodies in membranous nephropathy
(MN) raises questions about their pathogenetic and clinical meaning. This study sought to deﬁne antibody
isotypes and correlations; to compare levels in MN, other glomerulonephritides, and controls; and to determine
their association with clinical outcomes.
Design, setting, participants, & measurements Serum IgG1, IgG3, and IgG4 against aldose reductase (AR), SOD2,
and a-enolase (aENO)weremeasured at diagnosis in 186 consecutiveMN patients, in 96 proteinuric controls (36
with FSGS, and 60 with IgA nephropathy), and in 92 healthy people recruited in four Italian nephrology units.
Anti-phospholipase A2 receptor (PLA2r) and anti-neutral endopeptidase (NEP) IgG4 were titrated in the same
specimens. Association with 1-year follow-up clinical parameters was studied in 120 patients.
Results IgG4 was the most common isotype for all antibodies; IgG1 and IgG3 were nearly negligible. IgG4 levels
were positive in a signiﬁcant proportion ofMNpatients (AR, 34%; SOD2, 28%;aENO, 43%). Antibody titerswere
higher in MN than in healthy and pathologic controls (P,0.005). Anti-NEP IgG4 did not differ from normal
controls (P=0.12). Anti-PLA2r IgG4 was detected in 60% of patients and correlated with anti-AR, anti-SOD2, and
anti-aENO IgG4 (P,0.001). In MN patients negative for the whole antibody panel (20%), 1-year proteinuria
was lower compared with patients with at least one antibody positivity (P,0.05).
Conclusions Our data suggest that IgG4 is the prevalent isotype for antibodies against cytoplasmic antigens of
podocytes (AR, SOD2, aENO). Their levels were higher than in other proteinuric glomerulonephritides and
in normal controls and were correlated with anti-PLA2r. Only baseline negativity for all known antibodies
predicted lower 1-year proteinuria.
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Introduction
Membranous nephropathy (MN) is a leading cause of
nephrotic syndrome in adults (1). Glomerular damage
is produced by the deposition of subepithelial im-
mune deposits that consist mainly of IgG4 and C5b-9
(2,3). The deﬁnition of causative autoantibodies and
their renal targets is essential to understand the mech-
anisms of disease development and progression.
Recent ﬁndings indicate that more than one podocyte
protein may act as an autoantigen in human MN (4).
Identiﬁed antigens are membrane proteins, such as phos-
pholipase A2 receptor (PLA2r) (5) and neutral endopep-
tidase (NEP) (6), and components of the cytoplasm, such
as aldose reductase (AR), SOD2, and a-enolase (aENO)
(7,8). Circulating levels of the corresponding autoanti-
body might be used as biomarker of disease activity.
With the exception of a report of maternal anti-NEP
antibodies in antenatal MN (6,9), data on autoantibod-
ies are limited to anti-PLA2r antibodies. Anti-PLA2r
IgG4 have been described as the largely predominant
circulating and glomerular isotype in MN patients (5).
They seem speciﬁc (89%) for idiopathic MN (10–12)
and can be utilized as support to exclude secondary
MN (10). However, several MN patients are anti-
PLA2r negative (30%–50% according to case series)
whereas in others, anti-PLA2r positivity persists after
response to therapy (11,13). Data on anti-PLA2r do
not exclude the presence of other circulating autoan-
tibodies such as anti-cytoplasmic antigens of podocytes,
whose serum levels might be detected and might be
useful in clinical practice.
To test this hypothesis, we measured the levels of
antibodies against both membrane and cytoplasmic
autoantigens in patients with and without MN. Our
objectives were as follows: (1) to deﬁne the prevalent
isotype for each anti-cytoplasmic antibody and the spec-
trum of MN patients in respect to positivity or negativ-
ity for the whole panel of currently known antibodies;
(2) to compare their levels in participants with MN ver-
sus patients suffering from other proteinuric glomerular
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diseases or normal controls; and (3) to ascertain whether
a relationship exists between the type and level of these
antibodies and clinical outcome in individuals with MN.
Materials and Methods
Assembled Cohort
We conducted a retrospective study at four Italian
nephrology centers in Parma, Modena, Milano, and Bari.
We recruited patients with newly diagnosed MN or other
proteinuric nephropathies and normal controls over 2 years
(2008–2010). Ethical approval to test antibody levels was
obtained from the Giannina Gaslini Institute Ethics Com-
mittee. The study was registered in the EudraCT registry
(EudraCT 2011–003942–41).
MN Patients. We recruited 186 consecutive patients
with idiopathic MN, who gave informed consent to have
the serum antibody levels titrated at the time of renal biopsy,
before any therapy was started (Table 1). At the time enroll-
ment was closed, 120 patients had completed a follow-up of
12 months or longer, during which they had received differ-
ent therapy schemes, mainly the Ponticelli schedule (Supple-
mental Table 1). Criteria for enrollment were as follows:
histologically proven MN; negative tests for serum autoanti-
bodies (antinuclear antibody, ANCA), cryoglobulins, and
viral markers (hepatitis B surface antigen, HIV); absence of
any clinical suspicion of secondary MN; or absence of any
previous immunosuppressive treatment.
Proteinuric Controls. Ninety-two patients with different
nephropathies were recruited at the same institutions: 32
patients with FSGS and 60 with IgA nephropathy (IgAN).
Diagnosis was always based on histologic criteria. To pro-
vide similar clinical conditions to MN patients, FSGS spec-
imens were all collected during a relapse of nephrotic
proteinuria. IgAN patients had to present with proteinuria
.0.3 g/d and to be free of any immunosuppressive ther-
apy at the time of serum collection (Table 1).
Normal Controls. Serum was obtained from 96 normal
controls recruited at the same institutions. They consisted
of normal blood donors who had at least one normal
urinalysis and serum tests in the prior 6 months (Table 1).
Assays for Autoantibodies
Anti-AR, Anti-SOD2, and Anti-aENO. Circulating IgG1,
IgG3, and IgG4 levels against AR, SOD2, and aENO in sera
were determined with dot blot utilizing recombinant pro-
teins ﬁxed to nitrocellulose as antigens, as previously de-
scribed (7,8). Details of the method and examples of
variable positivity are given in the Supplemental Methods
and Supplemental Figure 1. Antibody positivity was deﬁned
as a serum level exceeding the 95th percentile of levels
titrated in normal controls.
Anti-PLA2r. Circulating anti-PLA2r IgG4 antibodies
were titrated by Western blot against podocyte protein
extracts (kindly offered by Dr. Saleem, University of Bristol,
Bristol, UK) previously separated in gradient monodimen-
sional electrophoresis (14) and then incubated with serum.
The technique is described in detail in the Supplemental
Methods. Anti-PLA2r autoantibodies were also evaluated
in a random subsample of MN patients (n=73) by indirect
immunoﬂuorescence with a commercially available test,
according to the manufacturer’s instructions (Euroimmun,
Lubeck, Germany) (15). Details of the method are given in
the Supplemental Methods and Supplemental Table 2.
Anti-NEP. Circulating IgG4 antibodies against NEP
were assessed by dot blot utilizing recombinant NEP as
ﬁxed antigen. The assay is based on the same technique
described for anti-AR, anti-SOD2, and anti-aENO, and is
reported in the Supplemental Methods.
Statistical Analyses
Data were described using frequencies, means, and SDs,
as appropriate. Natural log transformation was performed
on non-normally distributed variables before using linear
models. Due to the presence of several “zeros,” baseline
correlations were performed using the Spearman rank cor-
relation method for non-normally distributed variables;
natural log transformation was performed after adding
0.01 to each variable value. The Mann–Whitney U test
was used to compare non-normally distributed variables.
Separate univariable logistic models were used with pres-
ence of MN versus other nephropathies or controls as
binary outcomes to estimate the area under the receiver
operating characteristic (ROC) curves. Logistic regres-
sion models of 1-year proteinuria were built on log2-
transformed antibody values adjusting for baseline levels
of log2-proteinuria. Two models were built with the dichot-
omous outcome deﬁned as complete or partial remission
(proteinuria ,0.3 or ,3.5 g/d). Linear regression models
Table 1. Clinical characteristics of patients and controls enrolled in this study
MN (n=186) FSGS (n=32) IgAN (n=60) Normal (n=96)
Male sex 121 (65) 19 (59) 38 (63) 56 (58)
Age (yr) 59616 1863 4064 49610
Race
Caucasian 184 (99) 32 (100) 56 (93) 96 (100)
other 2 (1) 4 (7)
Diabetes 24 (13) 0 (0) 4 (7) 0 (0)
Serum creatinine (mg/dl) 1.1 (0.3–6) 0.6 (0.3–1) 0.9 (0.5–1.3) 0.9 (0.6–1.2)
Proteinuria (g/d) 5.8 (0.3–28) 6.0 (3.6–12.4) 1.55 (0.9–3.4) 0
Data are presented as n (%) or mean6 SD, or as median (range) for those with non-normal distribution. Clinical data were collected at
the time of serum sample collection. Proteinuria in normal controlswas tested byurine dipstick.MN,membranous nephropathy; IgAN,
IgA nephropathy.
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of log2-proteinuria adjusted for baseline proteinuria were
also built on each antibody level. Similarly, linear models
were used to study the associations between levels of anti-
bodies and serum albumin. Models with only one antibody
at a time were built for reasons of colinearity. Model as-
sumptions and goodness of ﬁt were veriﬁed looking at for-
mal tests and graphical tests based on residuals. All
statistical analyses were performed with STATA/MP 12.1
software (StataCorp, College Station, TX).
Results
Patients with MNwere prevalently male (65%) and had a
mean age of 59616 years. All were proteinuric at the time
of enrollment and had variable creatinine levels (Table 1).
Patients with FSGS (59% male) had proteinuria .3.5 g/d,
had normal renal function in all cases, and were younger
(age 1863 years). IgAN patients (63% male; 4064 years)
had proteinuria 0.9–3.4 g/d and normal renal function.
Normal controls were prevalently male (58%) with a
mean age of 49610 years (Table 1).
Antibody Levels in MN and in Other
Glomerulonephritides
Anti-AR, Anti-SOD2, and Anti-aENO Antibody Isotypes/
Serum Levels. Circulating anti-AR, anti-SOD2, and anti-
aENO isotypes (IgG1, IgG3, and IgG4) and levels were de-
termined by dot blot in the serum of 186 MN patients at
diagnosis (Figure 1). Isotype characterization of each spec-
iﬁcity indicated that IgG4 is the predominant IgG subclass.
Anti-AR and anti-SOD2 IgG1 and IgG3 were, in fact, only
sporadically positive (,3%). Anti-aENO IgG1–3 were in-
stead increased in a small but signiﬁcant proportion of MN
patients (13% IgG1 and 7% IgG3) (Supplemental Figure 2).
In patients with other nephropathies, serum levels of each
IgG4 antibody were found to be lower than in normal con-
trols; one IgAN patient presented an isolated anti-aENO
positivity (Figure 1). The percentage of MN patients with
IgG4 positive levels was highly signiﬁcant (AR, 34%; SOD,
26%; aENO, 43%; P,0.001 for all) (Supplemental Figure 3).
Comparison of levels conﬁrmed signiﬁcantly higher circu-
lating levels of anti-AR, anti-SOD2, and anti-aENO IgG4 in
MN patients compared with either normal participants or
other nephropathies (Table 2). The area under the ROC
curves for each antibody was signiﬁcantly greater in MN
patients compared with patients with other nephropathies
or normal participants, although to a lesser extent (Figure 2).
Anti-PLA2r and Anti-NEP Antibodies. Anti-PLA2r
IgG4 was detected by Western blot in 111 MN patients
(Figure 3), giving a ﬁnal estimate of 60% of patients being
positive (Supplemental Figure 3), conﬁrming previous
studies (5,10). In a random portion of MN sera (73 pa-
tients), anti-PLA2r total IgG as determined by indirect im-
munoﬂuorescence (12,15) conﬁrmed results of Western
blot titration (Spearman analysis, r=0.91; P,0.001) (Sup-
plemental Table 2). Anti-NEP IgG4 serum levels were de-
termined with dot blot analysis. The results shown in
Figure 3 indicate a minor percentage (17%) of MN patients
with anti-NEP positivity. NEP serum levels were not
higher in MN patients than in normal serum (P=0.12)
(Table 2).
Multiple Positivity. Many MN patients presented con-
comitant high serum levels of more than one antibody.
Anti-PLA2r serum levels correlated with all the other
antibodies and anti-AR correlated with anti-SOD2 (Table 3)
(P,0.001 in all cases). Simultaneous multiple positivity or
negativity for the antibody panel was tested in the whole
cohort of patients: 19 sera (10%) were completely positive
and 37 (20%) were negative. Most patients (70%) presented
intermediate positivity for one, two, or three antibodies
Figure 1. | Serum antibodies against cytoplasmic antigens of podocytes are increased in a significant portion of MN patients. Circulating
IgG4 (A) anti-AR, (B) anti-SOD2, and (C) anti-aENO in MN and control populations are shown. In all cases, we utilized a technique based on
dot blot analysis with recombinant protein linked to nitrocellulose as an antigen (Supplemental Figure 1). Results are given as chemi-
luminescence OD arbitrary units that corresponds to one unit of signal intensity of chemiluminescence detected by VersaDoc and computed
with QuantyOne software (Bio-Rad). The horizontal line is set at the 95th percentile of levels titrated in normal controls. AR, aldose reductase;
aENO, a-enolase; MN, membranous nephropathy.
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(Table 4). Of the 75 anti-PLA2r–negative patients, 38 (51%)
were positive for at least one other antibody (Supplemen-
tal Figure 4).
Clinical Correlations
There was no relationship between antibody levels and
proteinuria, renal function, and histologic stage at baseline.
No histologic or clinical characteristics distinguished anti-
PLA2r–positive and anti-PLA2r–negative patients. Antibody
levels failed to predict the probability to reach complete
(,0.3 g/d) or partial (, 3.5 g/d) remission after 1 year.
When proteinuria was modeled as a continuous variable,
only anti-AR IgG4 levels predicted 1-year proteinuria. Sim-
ilarly, only anti-aENO IgG4 signiﬁcantly predicted serum
albumin levels at 12 months (Supplemental Table 3).
Finally, 27 MN patients who were negative for all
antibodies completed the 12-month follow-up (Table 4).
Although treatment did not differ, they presented a mild
tendency to have a better outcome. In fact, compared with
MN patients who were positive for at least one antibody,
completely negative patients had signiﬁcantly lower 1-year
proteinuria (Mann–Whitney test, P=0.03), at 0.33 g/d (inter-
quartile range, 0.1–1.8) versus 1.50 g/d (interquartile range,
0.2–4.2). A borderline signiﬁcantly higher remission rate was
also present in negative patients (48% versus 27%; P=0.07).
Discussion
The recent discovery that podocyte proteins are targets of
circulating antibodies in human MN represented a break-
through in the research on MN pathogenetic mechanisms
(5,7,8). However, the implication of more than one antigen
in the formation of subepithelial immune deposits raises
questions about the clinical signiﬁcance of each autoanti-
body. Thus far, four podocyte antigens have been studied
in primary MN: PLA2r was the ﬁrst discovered (and
deeply investigated) (5,11,13), and AR, SOD2, and aENO
were subsequently identiﬁed (7,8). Our study was planned
to bridge the gap of knowledge on antibodies against neo-
expressed cytoplasm antigens (i.e., anti-AR, anti-SOD2,
and anti-aENO). In fact, there is little information in the
literature about their serum levels and their correlation
with anti-PLA2r. Moreover, the evaluation of a potential as-
sociation of serum antibody levels (including anti-PLA2r)
with clinical outcomes requires studies in large cohorts of
patients. Our strategy was therefore based on the concomi-
tant determinations of serum levels of anti-cytoplasmic
Table 2. Levels of circulating antibodies in MN patients, controls, and other nephropathies
MN Controls FSGS IgAN
Anti-AR 37.90 (7.12–121.90) 29.67 (9.39–47.36)a 6.38 (3.43–9.15b 9.39 (4.41–14.46)b
Anti-SOD2 84.34 (35.51–223.60) 33.92 (4.11–62.23)b 6.89 (4.16–9.69)b 9.09 (3.93–12.99)b
Anti-aENO 110.40 (27.84–237.70) 47.80 (31.09–67.38)b 5.40 (3.29–9.43)b 9.31 (5.06–18.19)b
Anti-NEP 53.52 (3.52–211.20) 32.42 (14.95–54.73) 4.08 (2.08–6.92)b 7.05 (3.67–11.39)b
Anti-PLA2r 40.26 (13.12–96.76) Undetectable —— ——
Data are expressed as chemiluminescence OD arbitrary units and presented as median (interquartile range). Only data of 111 positive
patients were reported for anti-PLA2r. MN, membranous nephropathy; IgAN, IgA nephropathy; AR, aldose reductase; aENO,
a-enolase; NEP, neutral endopeptidase; PLA2r, phospholipase A2 receptor.
aA highly statistically signiﬁcant difference with MN level (two tailed Mann–Whitney U test). P=0.004.
bA highly statistically signiﬁcant difference with MN level (two tailed Mann–Whitney U test). P,0.001.
Figure 2. | ROC curves. The area under the ROC curves for each antibodywas significantly greater in MN patients compared with (A) patients
with other nephropathies or (B) normal participants, although to a lesser extent. ROC, receiver operating characteristic; MN, membranous
nephropathy.
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antigen antibodies and comparisons with anti-PLA2r in the
same patient population.
Our results showed that high levels of circulating anti-
bodies against cytoplasm podocyte proteins (AR, SOD2,
and aENO) are present in a signiﬁcant number of MN
patients. The predominant isotype was IgG4 in all cases,
although anti-aENO IgG1–3 levels were not completely
negligible. On the other hand, circulating levels of IgG4
anti-PLA2r and other IgG4 antibodies correlated at the
time of diagnosis, suggesting a common formation mech-
anism. Anti-NEP IgG4 seemed to play a secondary role.
Some limitations of this study must be acknowledged.
Follow-up sera were not available, and thus we could not
perform a lengthwise evaluation of autoantibody levels
and laboratory parameters. Further studies, now in prog-
ress, will bridge this knowledge gap. Moreover, circulating
serum IgG subclass measurement was not available. A
correlation of single speciﬁcities with the respective total
IgG isotype level could not be veriﬁed. Truthfully, none of
the previous seminal studies on anti-podocyte antibodies in
MN reported such data (5,10–12); when planning brand
new studies on MN, researchers will need to consider
this recurring limitation. Lastly, a group of secondary
MN was not available for comparison; a deﬁnitive evalu-
ation of the speciﬁcity of anti-cytoplasmic podocyte anti-
gen antibodies is not possible with the data analyzed in
our study.
Despite the considerations above, our study is the ﬁrst
to attempt correlating serum levels of different antibody
speciﬁcity in the same population. Owing to the large
number of patients recruited and the fact that they were all
enrolled at the time of disease diagnosis (patients recruited
in other studies had a variable disease duration from 4 to
144 months), our results add signiﬁcant knowledge to the
studies on MN that evaluated only anti-PLA2r antibodies.
Moreover, our study adds relevant data on the deﬁnition of
anti-PLA2r outliers (i.e., patients who are anti-PLA2r neg-
ative despite an active disease). Indeed, we found that
only 37 patients (20%) were negative for all antibodies, a
small proportion of those negative for anti-PLA2r alone
(40%). Interestingly, only negativity for the complete panel
is associated with lower proteinuria after 1 year. Although
no single antibody level has signiﬁcant independent prog-
nostic ability, negativity to all antibodies does. Our data
cannot help understand whether this subgroup
represents a different pathologic entity or a MN cluster
with immunologic inactive disease that evolves toward
spontaneous remission. However, recent advice to dose
Figure 3. | Serum levels of circulating anti-PLA2r and anti-NEP IgG4. (A) Anti-PLA2rwas revealed utilizing aWestern blot assaywith podocyte
extracts as a fixed antigen. PLA2r was previously recognized by specific antibodies in the area of the gel between 116 and 220 kDwhere PLA2r
was the unique spot (Supplemental Figure 1). Anti-PLA2r serum positivity was validated with a semiquantitative immunofluorescence test
(Supplemental Table 2). (B) Anti-NEP IgG4 was determined with dot blot analysis (Supplemental Figure 1). The horizontal line is set at the 95th
percentile of levels titrated in normal controls. Anti-PLA2r, anti-phospholipase A2 receptor; anti-NEP, anti-neutral endopeptidase.
Table 3. Spearman’s rank correlation coefficient between
serum antibodies titers at the time of diagnosis in MN patients
SOD2 aENO PLA2r
AR 0.385a 0.166 0.47a
SOD2 0.097 0.36a
aENO 0.37a
Data are expressed as r for each correlation. MN, membranous
nephropathy; aENO, a-enolase; PLA2r, phospholipase A2 re-
ceptor; AR, aldose reductase.
aIndicates an highly statistically signiﬁcant correlation
(P,0.001).
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anti-PLA2r to deﬁne MN activity (16,17) and thus to drive
the therapeutic approach is challenged by the results of this
study. Further data from different MN cohorts are needed
to conﬁrm the advantage of the use of the complete panel
of antibodies to individualize the therapeutic approach.
A few considerations on MN pathogenesis emerge from
this study. The ﬁrst consideration is the temporal sequence
of autoantibody production. Although this should be proven
in an experimental model, we propose that the temporal
appearance of detectable antibodies may follow a common
mechanism. Although we cannot evaluate the timing of
antibody production in the preclinical phase, it is possible
that podocyte overexpression and de-localization of SOD2
and AR may represent an antioxidant response preceding
the humoral immune response. In Heymann nephritis
(18,19), podocyte-produced oxygen radicals in the presence
of C5b-9 mediate glomerular damage (20,21). In this light,
anti-SOD2 and anti-AR antibodies should follow a ﬁrst au-
toimmune phase. However, autoantibody formation in MN
may require a more complex and disease-speciﬁc mecha-
nism than a generic podocyte injury, as conﬁrmed by the
minimal antibody serum levels in FSGS, the prototype of
podocytopathy. In fact, we showed a lower circulating
level of anti-AR, anti-SOD2, and anti-aENO in IgAN and
FSGS compared with normal controls (as conﬁrmed by the
better performance of ROC curves comparing MN with
other nephropathies). These data suggest an effect of pro-
teinuria and/or minor total Ig serum levels in lowering
anti-cytoplasmic podocyte antigen antibodies and support
the concept that the production of such antibodies is a
disease-speciﬁc mechanism in MN.
A second consideration concerns the role of a2enolase.
Circulating anti-aENO IgG has been reported in various
autoimmune diseases (22–24). When characterized, the
prevalent isotype was of the IgG1 and IgG3 subclasses also
in previous reports on MN patients (25), whereas anti-aENO
IgG4 seems to be more speciﬁc for MN (8). Because the shift
from IgG1 to IgG4 formation is a slow process that requires a
complex machinery involving T helper-2, B cell activation,
and IL-3/13/10 (26), the prevalence of IgG4 in the serum
and within the glomeruli of MN patients suggests that the
isotype switch may be a speciﬁc mechanism of the disease
rather than a marker of inﬂammation. Because our data do
not allow any conclusion on the role of anti-aENO IgG1 and
IgG3 in MN, we cannot exclude that they are also involved
in immune-deposit formation and podocyte damage.
In conclusion, our study demonstrates that all recently
described serum anti-podocyte antibodies are increased in
MN at diagnosis. Although no strong association with
clinical outcome was found for any single autoantibody,
follow-up proteinuria is lower in patients who are negative
for all antibodies. A panel including all antibodies is therefore
the most promising biomarker to be tested and utilized in
prospective studies.
Coexistence of autoantibodies suggests a complex path-
ogenetic pathway that involves different podocyte targets.
New experimental models are needed to elucidate the ap-
pearance time and the role of each anti-podocyte antibody
in MN development and progression.
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